FDA Approval Activities for this Drug
Requip (ropinirole hydrochloride) Tablets, GlaxoSmithKline NDA 20-658 / S012 | REQUIP (ropinirole hydrochloride) Tablets, SmithKline Beecham, New or Modified Indication | Ropinirole Hydrochloride Tablets, Roxane Labs, Tentative Approval | Ropinirole Hydrochloride Tablets, Par Pharma, Tentative Approval | Ropinirole Hydrochloride Tablets, Par Pharma, Tentative Approval | Ropinirole Hydrochloride Tablets, Teva Pharma, Tentative Approval | Ropinirole Hydrochloride Tablets, Mylan Pharmaceuticals Inc., Approval | Ropinirole Hydrochloride Tablets, Teva Pharmaceuticals, Approval | Ropinirole Hydrochloride Tablets, Roxane Laboratories, Inc., Approval | Ropinirole Hydrochloride Tablets, Par Pharmaceutical, Inc., Approval | Ropinirole Hydrochloride Tablets, Corepharma, LLC, Approval | Ropinirole Hydrochloride Tablets, Wockhardt USA, Inc., Approval | Requip XL (ropinirole) Extended-Release Tablets, GlaxoSmithKline, Approval | Requip XL (ropinirole) Extended-Release Tablets, GlaxoSmithKline, Approval | Requip XL (ropinirole hydrochloride) Extended-Release Tablets, GlaxoSmithKline, Formulation Revision | Requip (ropinirole hydrochloride) Tablets, GlaxoSmithKline, Labeling Revision | Requip XL (ropinirole hydrochloride) Extended-Release Tablets, GlaxoSmithKline, Formulation Revision | Ropinirole Hydrochloride Tablets, Zydus Pharmaceuticals USA, Inc., Approval